Find the financial assistance that is right for you

Bayer provides financial support to eligible STIVARGA^® (regorafenib) patients*

Access Services by Bayer^TM can connect eligible STIVARGA patients to available affordability support options. Call 1-800-288-8374 to learn more.

$0 Co-Pay for eligible patients*

Eligible commercially insured patients may pay as little as $0 per month

Currently, $0 Co-Pay is available through specialty pharmacy providers (SPPs) and online

Up to the program maximum. Benefit limitations apply
Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible
Full terms and conditions apply*

Enroll Online

Visit

zerocopaysupport.com

Patient Enrollment

Patient can enter their personal information to instantly obtain a Co-Pay Card

Use

Add Co-Pay Card as secondary payer for immediate coverage

For more information on enrolling online, call 1-647-245-5622 8:00 AM–8:00 PM EST/EDT, Monday–Friday

If you cannot afford your prescription medication, Bayer may be able to help.

The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please contact the program at 1-866-2BUSPAF (228-7723) Monday–Friday, 9:00 AM–6:00 PM EST, or visit the foundation website at www.patientassistance.bayer.us to see if you may qualify for assistance.

INDICATIONS

STIVARGA (regorafenib) is a prescription medicine used to treat adults with:

colon or rectal cancer that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines
a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines
a type of liver cancer called hepatocellular carcinoma (HCC) in people who have been previously treated with sorafenib

It is not known if STIVARGA is safe and effective in children less than 18 years of age.

IMPORTANT SAFETY INFORMATION

STIVARGA (regorafenib) can cause severe liver problems, including increased blood ammonia, which can sometimes lead to death. Your healthcare provider will do blood tests to check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems.

Tell your healthcare provider right away if you get any of these signs or symptoms of liver problems during treatment:

yellowing of your skin or the white part of your eyes (jaundice)
pain on the upper right side of your stomach area (abdomen)
nausea or vomiting
loss of appetite
light-colored stools (bowel movements)
dark “tea-colored” urine
severe headache or headaches that persist
vision changes
seizures
feeling more tired than usual
drowsiness
trembling
confusion
memory loss or disorientation

Before taking STIVARGA, tell your healthcare provider about all of your medical conditions, including if you:

have liver problems in addition to liver cancer
have bleeding problems
have high blood pressure
have heart problems or chest pain
plan to have surgery or have had a recent surgery. You should stop taking STIVARGA at least 2 weeks before planned surgery
are pregnant or plan to become pregnant. STIVARGA can harm your unborn baby.
- Females should use effective birth control during treatment with STIVARGA and for 2 months after your final dose of STIVARGA. Tell your healthcare provider right away if you become pregnant during treatment with STIVARGA or within 2 months after your final dose of STIVARGA.
- Males with female partners who can become pregnant should use effective birth control during treatment with STIVARGA and for 2 months after your final dose of STIVARGA.
are breast-feeding or plan to breast-feed. It is not known if STIVARGA passes into your breast milk. Do not breastfeed during treatment with STIVARGA and for 2 weeks after your final dose of STIVARGA.

Tell your healthcare provider about all the prescription and over-the-counter medicines, vitamins, and herbal supplements you take. Avoid drinking grapefruit juice and taking St. John’s Wort while taking STIVARGA.

STIVARGA may cause serious side effects, including:

infection. STIVARGA may lead to a higher risk of infections especially of the urinary tract, nose, throat and lung. STIVARGA may lead to a higher risk of fungal infections of the mucous membrane, skin or the body. Tell your healthcare provider right away if you get fever, severe cough with or without an increase in mucus (sputum) production, severe sore throat, shortness of breath, burning or pain when urinating, unusual vaginal discharge or irritation, redness, swelling or pain in any part of the body.
severe bleeding. STIVARGA can cause bleeding, which can be serious and sometimes lead to death. Tell your healthcare provider if you have any signs of bleeding while taking STIVARGA, including: vomiting blood or if your vomit looks like coffee grounds, pink or brown urine, red or black (looks like tar) stools, coughing up blood or blood clots, menstrual bleeding that is heavier than normal, unusual vaginal bleeding, nose bleeds that happen often, bruising, and lightheadedness.
a tear in your stomach or intestinal wall (bowel perforation). STIVARGA may cause a tear in your stomach or intestinal wall (bowel perforation) that can be serious and sometimes lead to death. Tell your healthcare provider right away if you get severe pains or swelling in your stomach area (abdomen), fever, chills, nausea, vomiting, or dehydration.
a skin problem called hand-foot skin reaction and severe skin rash. Hand-foot skin reactions are common and sometimes can be severe. Tell your healthcare provider right away if you get redness, pain, blisters, bleeding, or swelling on the palms of your hands and soles of your feet, or a severe rash.
high blood pressure. Your blood pressure should be checked every week for the first 6 weeks of starting STIVARGA. Your blood pressure should be checked regularly and any high blood pressure should be treated while you are receiving STIVARGA. Tell your healthcare provider if you have severe headaches, light-headedness, or changes in your vision.
decreased blood flow to the heart and heart attack. Get emergency help right away if you get symptoms such as chest pain, shortness of breath, feel dizzy, or feel like passing out.
a condition called Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Call your healthcare provider right away if you get severe headaches, seizure, confusion, change in vision, or problems thinking.
risk of wound healing problems. Wounds may not heal properly during STIVARGA treatment. Tell your healthcare provider if you plan to have any surgery before starting or during treatment with STIVARGA.
- You should stop taking STIVARGA at least 2 weeks before planned surgery.
- Your healthcare provider should tell you when you may start taking STIVARGA again after surgery.

The most common side effects with STIVARGA include pain including stomach-area (abdomen); tiredness, weakness, fatigue; diarrhea (frequent or loose bowel movements); decreased appetite; infection; voice change or hoarseness; increase in certain liver function tests; fever; swelling, pain, and redness of the lining in your mouth, throat, stomach, and bowel (mucositis); and weight loss.

Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

For important risk and use information about STIVARGA, please see the full Prescribing Information, including Boxed Warning.

*PROGRAM DETAILS:
Patients are eligible if they are commercially insured and may pay as little as $0 per month up to the program maximum. Benefit limitations apply. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. Full terms and conditions apply, see www.zerocopaysupport.com.

PATIENT INSTRUCTIONS:
After enrolling in the program, present this card and your insurance card along with a valid prescription at any participating pharmacy. By using this offer, you are certifying that you understand and agree to comply with the program restrictions section below. Patients with questions about the Stivarga Co-Pay Savings Program should call 1-647-245-5622.

RESTRICTIONS:
This offer is valid in the United States. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state health programs (such as medical assistance programs). Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. By using this offer, the patient is certifying that they will comply with any terms of their health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. This program is not insurance. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. Program managed by ConnectiveRx on behalf of Bayer Pharmaceuticals. Bayer reserves the right to rescind, revoke or amend this offer without notice at any time.

PHARMACIST INSTRUCTIONS:
Submit the claim to the primary Third Party Payer first, then submit the balance due to SS&C as a Secondary Payer COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code (eg, 8). Patients are eligible if they are commercially insured and may pay as little as $0 per month up to the program maximum. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible.

This site is intended for US audiences only.

Last updated on September 2026